BRUSSELS (dpa-AFX) - Siemens Healthineers AG (SMMNY.PK, SHL.DE) and Novo, announced on Monday that they have agreed to work together to improve care for patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH).
The companies said the partnership will focus on raising disease awareness, supporting earlier assessment and expanding access to non-invasive blood testing. MASLD affects nearly a quarter of U.S. adults and is closely linked to obesity, type 2 diabetes and cardiovascular disease.
Siemens Healthineers noted its Enhanced Liver Fibrosis (ELF) test is the first U.S.-authorized blood test to help clinicians assess risk of progression in patients with advanced fibrosis due to MASH. The test is available through national laboratories and covered by a CPT code.
The companies said the collaboration aims to reduce reliance on invasive procedures such as liver biopsy and create a more effective pathway for disease management across health systems.
On the XETRA, shares of Siemens Healthineers were gaining 0.61 percent, changing hands at 38.00 euros.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
